<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="153">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04555096</url>
  </required_header>
  <id_info>
    <org_study_id>COV-4419-201</org_study_id>
    <nct_id>NCT04555096</nct_id>
  </id_info>
  <brief_title>A Trial of GC4419 in Patients With Critical Illness Due to COVID-19</brief_title>
  <official_title>A Pilot, Randomized, Placebo-Controlled Trial of GC4419 (Avasopasem Manganese) in Patients With Critical Illness Due to SARS-CoV-2 Infection (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galera Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galera Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Trial of GC4419 in Patients with Critical Illness due to COVID-19
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>28 day all-cause mortality</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Covid19</condition>
  <condition>SARS-CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>Active GC4419</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Arm B</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC4419</intervention_name>
    <description>180 Minute IV Infusion</description>
    <arm_group_label>Active GC4419</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>180 Minute IV Infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects at least 18 years of age.

          2. Ability to understand and the willingness to sign a written informed consent.

          3. Laboratory-confirmed SARS-CoV-2 infection as determined by a positive PCR test
             documented prior to randomization

          4. Requirement for intensive inpatient hospital care

          5. Acute hypoxemic respiratory failure typifying ARDS

          6. Adequate liver function

          7. Use of effective contraception

        Exclusion Criteria:

          1. Expected survival for less than 48 hours after randomization

          2. Child-Pugh stage C hepatic impairment and/or portal hypertension secondary to
             cirrhosis

          3. Stage IV chronic kidney disease or end-stage kidney disease on maintenance
             hemodialysis

          4. Requirement for extra-corporeal membrane oxygenation (ECMO)

          5. Acute Myocardial Infarction (AMI)

          6. Active bleeding requiring transfusion

          7. Concurrent participation in another clinical trial of experimental treatment for
             SARSCoV-2

          8. Female patients who are pregnant or breastfeeding

          9. Requirement for concurrent treatment with nitrates
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon Holmlund, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Study Chair</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amanda Sanders</last_name>
    <phone>610-725-1500</phone>
    <email>info@galeratx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jon Holmlund, MD</last_name>
    <phone>610-725-1500</phone>
    <email>info@galeratx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mercy Research</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Analyn Howells</last_name>
      <phone>314-251-1481</phone>
    </contact>
    <investigator>
      <last_name>George Matuschak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 16, 2020</study_first_submitted>
  <study_first_submitted_qc>September 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2020</study_first_posted>
  <last_update_submitted>September 19, 2020</last_update_submitted>
  <last_update_submitted_qc>September 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID19</keyword>
  <keyword>SARS-CoV-2 Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

